Citations

Showing 10 of 108083 citations.

Identification of HER-2/neu peptide p373-382 as a naturally processed immunodominant HLA-A2 binding epitope (46.11)
Henle, Andrea M. , Erskine, Courtney L. , Benson, Linda M., Knutson, Keith L. , Knutson, Keith L.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 188 | Issue: 1_Supplement | Pages: 46.11-46.11

10.4049/jimmunol.188.supp.46.11 Get It

Abstract HER2 is a prime target for cancer therapeutics due to its high overexpression in tumors. Advanced clinical trials, in breast and prostate cancer, investigating the use of the HLA-A2-binding HER2 peptide p369-377 (E75) as a vaccine are ongoing. In the present study, we investigated the proteasomal processing of p369-377 and other epitopes from HER2. We did not detect processing of p369-377 by either the proteasome or immunoproteasome in vitro, suggesting that tumor cells do not naturally process this epitope from HER2 for presentation on HLA-A2. However, other HER2 peptides were found to be consistently processed by the proteasome and immunoproteasome. One newly identified processed peptide, HER2 p373-382, was found to bind HLA-A2 stronger than p369-377, despite algorithms that predicted p369-377 as a stronger binder. Cytotoxic T lymphocytes (CTL) specific for p373-382 recognized target cells pulsed with either p373-382 or p369-377. CTL specific for p373-382 also lysed HER2+HLA-A2+ human breast cancer cells more efficiently than p369-377-specific CTL. These results suggest that cancer cells are naturally processing and presenting p373-382. Furthermore, our results suggest that T cells generated against p369-377 in previous studies may have been cross-reacting with p373-382. Thus, the newly identified p373-382 peptide may be a more appropriate candidate for vaccines with this new evidence that it is processed and presented by HLA-A2 for recognition by HER2-specific CTL.
IL-9 strategy to perturb Treg function and enhance anti-tumor immunity (P4273)
Pollock, Kevin G. , Lustgarten, Joseph, Cohen, Peter A. , Gendler, Sandra , Hoelzinger, Dominique B. , Dominguez, Ana Lucía , Pollock, Kevin

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 190 | Issue: Supplement_1 | Pages: 140.9-140.9

10.4049/jimmunol.190.supp.140.9 Get It

Abstract IL-9 is a cytokine that is primarily associated with mast cells and airway inflammation, however it also plays a role in T regulatory cell (Treg) survival and recruitment to tumors. We previously reported that 4-1BB treatment of Tregs inhibits both Treg function and IL-9 secretion. Neutralization of IL-9 with an anti-IL-9 antibody inhibits the suppressive function of Tregs without affecting the function of CD4+ and CD8+ T effector cells. Furthermore, the combination of intra-tumoral CpG and anti-IL-9 induced tumor rejection in BALB-neuT and MUC1 tolerant transgenic mice. Here we show that the lack of IL-9 inhibits Treg suppression of T cell proliferation, using IL-9 knockout (IL-9ko) mice. Phenotypic analysis of Treg markers showed that tumor draining lymph nodes of 4T1 bearing mice contain fewer CTLA-4+ and CD103+ Tregs, and that these also have reduced of CTLA-4 and CD103 expression. We also observed that IL-9ko mice spontaneously reject TUBO and 4T1 mammary carcinoma cells and that rejection is abrogated by CD8+ T cell depletion. Finally, preliminary studies of human CD4+ T cell proliferation revealed that IL-9 neutralization led to greater proliferation than isotype control treated cells. Taken together our results suggest that IL-9 can have an immunosuppressive function that comes into play in the tumor microenvironment, and that the blockade of IL-9 could serve as a novel strategy to perturb the function of Tregs to enhance the antitumor effect of tumor vaccines.
Endogenous tumor-reactive CD8+ T cells are differentiated effector cells with high expression of CD11a and PD-1 but are unable to control tumor growth (P2089)
Gibbons, Rachel, Liu, Xin , Harrington, Susan M. , Krco, Christopher J., Markovic, Svetomir, Kwon, Eugene , Markovic, Svetomir N. , Dong, Haidong

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 190 | Issue: Supplement_1 | Pages: 170.1-170.1

10.4049/jimmunol.190.supp.170.1 Get It

Abstract We utilized CD11a, an integrin up-regulated on effector and memory CD8+ T cells, as a biomarker to identify, measure, and monitor endogenous tumor-reactive cytotoxic lymphocytes (CTLs) in two mouse tumor models and in melanoma patients. CD11ahigh CD8+ T cells were detected in primary and metastatic tumor sites after tumor cell injection, as well as in spontaneous murine breast cancer tissues. In the peripheral blood of melanoma patients, tumor antigen-specific T cells were detected within the population of CD11ahigh CD8+ T cells that express high levels of PD-1. Infusion of lethally irradiated tumor cells failed to stimulate the expansion of CD11ahigh CD8+ T cells, suggesting that the access of tumor cells to target tissues is required to induce CD11ahigh CD8+ T cell responses. Phenotypic analysis revealed that the CD11ahigh CD8+ T cells detected in our studies were proliferating (Ki67+) activated T cells (CD62L-, CD69+). Although CD11ahigh CD8+ T cells were differentiated effector cells with CTL effector functions, they were typically unable to control tumor growth in our mouse models, possibly due to high expression of PD-1. Our results demonstrate that CD11a can be used as a biomarker to identify and track endogenous tumor-reactive CTLs.
Increased innate immune recognition and viral clearance modulates the immune potential of an engineered CD8 T-cell vaccine (P4463)
Bell, Michael , Pease, Larry R. , Pavelko, Kevin D. , Bell, Michael

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 190 | Issue: Supplement_1 | Pages: 126.15-126.15

10.4049/jimmunol.190.supp.126.15 Get It

Abstract We have engineered an attenuated picornavirus vaccine using Theiler’s murine encephalomyelitis virus (TMEV) and are exploring its usefulness in immunotherapy. We find that two different insertion sites within the leader protein of the TMEV genome allow for effective production of virus vaccine strains. One site is at the amino terminal end of the protein after the third amino acid position (p3); the other is at the XhoI restriction site further downstream. We find that vaccine antigen insertion at p3 disrupts the ability of the virus to inhibit type I interferon production by infected cells, whereas XhoI insertion does not. Further, the p3 modified virus can be cleared from animals lacking functional T and B-cells but replicates to high titer in IFNα/β receptor knockout mice, suggesting that innate immune mechanisms are sufficient for viral clearance. In spite of rapid clearance, p3 vaccines readily stimulate proliferation of transgenic T-cells and induce de novo responses to T-cell antigens in wild-type mice, although to a lesser extent than the XhoI modified vaccines strains. The use of either vaccine however effectively delays tumor growth and enhances survival in mice bearing melanoma and breast tumors. This vaccine provides a safe and effective vaccine strategy for the induction of CD8+ T-cell immunity directed towards cancer and provides support for the development of picornaviruses as vaccine vectors for treating human disease.
A novel ELISA for eosinophil peroxidase provides a sensitive high throughput assay for eosinophil degranulation in either mouse or human biological samples (65.29)
Ochkur, Sergei I. , Protheroe, Cheryl, Nair, Parameswaran, Furuta, Glenn T. , Moqbel, Redwan, Kim, John , Lacy, Paige , Lee, James S. , Lee, Nancy

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 186 | Issue: 1_Supplement | Pages: 65.29-65.29

10.4049/jimmunol.186.supp.65.29 Get It

Abstract Eosinophils comprise only 1-3% of circulating leukocytes but are often a diagnostic feature associated with a variety of inflammatory and disease states, including parasitic and fungal infections, allergic diseases (e.g., asthma, rhinitis and sensitivities to specific foods), cancer, and transplant rejection. The accurate evaluations of eosinophilia as well as the release of stored eosinophil granule proteins are important for the monitoring disease progression and/or assessing the effectiveness of a given treatment strategy(ies). Despite the availability of detection methods for each of the eosinophil granule proteins logistical difficulties limiting either the assays specificity and/or sensitivity have prevented their extensive use. We have generated unique eosinophil peroxidase specific monoclonal antibodies (EPX-mAb) and a high throughput sandwich ELISA assay as a means of overcoming these difficulties. Our EPX-mAb based ELISA is ~10 times more sensitive than traditional OPD based activity assays and allows detection of EPX in mouse BAL fluid after an acute OVA protocol as well as EPX release from mouse eosinophils stimulated ex vivo. The assay is highly specific and gives no signal in samples from EPX deficient mice even with massive eosinophilia (e.g., EPX deficient IL-5 transgenic mice). More significantly, this assay detects EPX in human tissue extracts and biological fluids and thus represents novel diagnostic assay previously unavailable in clinical settings.
A mouse model of transient diabetes; a new perspective on glucose homeostasis (123.24)
Girtman, Megan A. , Pease, Larry R. , Pavelko, Kevin D.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 188 | Issue: 1_Supplement | Pages: 123.24-123.24

10.4049/jimmunol.188.supp.123.24 Get It

Abstract We have induced acute diabetes following immune attack on the pancreas with islet specific CD8+ T cells, but surprisingly many animals subsequently recovered blood glucose homeostasis. The recovered animals exhibited nearly normal glucose tolerance and produced normal levels of blood insulin following glucose challenge. Remarkably very few islets were present in these animals and those remaining were virtually insulin free. In this model B6 RIP-OVAhi mice receive 100 to 600 naïve OT-1 CD8+ T cells prior to activation by an infection with Theilers murine encephalomyelitis virus encoding the SIINFEKL ovalbumin antigen. When greater numbers of T cells are transferred, this protocol causes acute and fatal diabetes. However, when limiting numbers of T cells are used, animals can recover from the acute phase of the disease. Under these limiting conditions, we find that the mice develop acute pancreatitis by day 5 following infection and stop producing insulin by day 8. By day 11 to 14 some animals begin to recover. Early in the recovery process, insulin positive beta cells are evident in islets. However, late after recovery (days >56) animals that regulate blood sugar normally are found devoid of insulin producing beta cells, though insulin levels are near normal. This raises important questions about how these animals recover glucose homeostasis following cellular immune attack on their islets. Our hypothesis is that insulin is produced outside of the pancreas in these animals.
Culture conditions promoting innate immunity and homeostatic proliferation generate highly enriched, MUC1- or HER2/neu-specific CD4+ and CD8+ T cells (P4419)
Cohen, Peter A. , Pathangey, Latha , Gorman, Jessica E., Viso, Carole, Gendler, Sandra , McCurry, Dustin , Disis, Mary Lenora

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 190 | Issue: Supplement_1 | Pages: 205.19-205.19

10.4049/jimmunol.190.supp.205.19 Get It

Abstract Although tumors from melanoma patients can often provide a source of therapeutically active T cells for adoptive therapy, it has historically proved challenging to employ peripheral blood as the T cell source for any type of cancer. We have observed nonetheless that HER2-specific T cells can be Ag-driven and enriched in culture when PBMCs from HER2-vaccinated breast cancer patients are treated with exogenous IL12. We hypothesized that stimulating innate immunity could further improve PBMC cultures by activating the DC subpopulation more effectively than adding exogenous rIL12. Bulk PBMC exposure to optimized TLR agonists produced vast quantities of IL12 and IL23, and upregulated HLA-DR, B7.1 and CD40 in the DC subpopulation, effects not produced by exogenous IL12. Subsequent IL7 exposure emulated homeostatic proliferation, selectively causing the Ag-driven T cell subset both to proliferate faster and to strongly resist apoptosis. Ag-specificity within two weeks approached 80-100% of both CD4+ and CD8+ T cells for recall Ags and 1-15% for a wide array of MUC1- and HER2-derived peptides, including the ability to distinguish glycoforms. Culture-expanded T cells retained a young CD28+/CD56- phenotype, uniformly expressed ROR-γ during culture, variably produced IL-2 and/or IL-17, and uniformly expressed T-bet and secreted IFN-γ when reexposed to Ag. Such T1/T17 bipotency may be ideal for anti-tumor adoptive therapy and highly efficient for use in Ag discovery.
CD8+ T cells in a normal host limit autoimmune attack by CD-8+ effector T cells (P4541)
Girtman, Megan A. , Pease, Larry R. , Pavelko, Kevin D.

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 190 | Issue: Supplement_1 | Pages: 197.5-197.5

10.4049/jimmunol.190.supp.197.5 Get It

Abstract We have developed a mouse model of diabetes by adoptively transferring small numbers of OT1 cells into animals expressing OVA under the rat insulin promoter (RIP-OVA). These cells are activated in vivo with a Picornavirus (TMEV) expressing OVA antigen. Titrating the dose of adoptively transferred cells, changes disease outcome. Mice receiving low amounts of cells develop hyperglycemia, and recover homeostasis. Investigation of recovered animals revealed normal blood glucose regulation. Pancreatic histology of recovered mice showed extensive pancreatic destruction with no or very few remaining insulin-positive islets. While adoptively transferred OT1 cells were present, pancreas infiltrating T cells were largely endogenous. To evaluate the functional importance of the host T cells, we tested disease progression using RAG KO, CD4 KO, and CD8 KO RIP-OVA hosts. Without RAG, CD4, or CD8 we observed increased disease severity. This change is not attributed to homeostatic proliferation in the CD4 and CD8 KO animals, as adoptively transferred OT1 cells behaved similarly in the KO hosts in comparison to RIP-OVA mice. However there is significant homeostatic proliferation occurring in the RIP-OVA RAG KO animals. Our studies reveal the importance of CD4 and CD8 T cells in limiting autoimmune attack in the pancreas. Although populations of CD4 T regulatory cells are well known, the importance of CD8 T cells in limiting inflammation are less well characterized.
Lung dysfunction in a mouse model of inflammation is dependent on T-cell-independent IL-13 expression (54.18)
Sergei, Ochkur, Wen, Li , Zellner, Katie R. , Colbert, Dana, Protheroe, Cheryl, Jacobsen, Elizabeth A. , Lee, James , Lee, Nancy

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 186 | Issue: 1_Supplement | Pages: 54.18-54.18

10.4049/jimmunol.186.supp.54.18 Get It

Abstract Chronic asthma is characterized by pulmonary remodeling and sustained lung dysfunction. The expression of IL-13 has been demonstrated as sufficient and necessary to induce these pathologies. Despite the common assumption that T cells are the primary source of IL-13 in the lung following allergen provocation, the mechanistic events leading to IL-13 expression are unclear, including the potential importance of other cells (i.e., non-T cells). Methods: Co-expression of IL-5 and eotaxin-2 induces pulmonary histopathologies and lung dysfunction that are eosinophil-dependent (i.e., they are absent in triple transgenic I5/hE2/PHIL) animals. IL-13 knockout and CD4 knockout mice were crossed with I5/hE2 mice to assess the effects of these deficiencies on the induced pathologies occurring in this double transgenic model. Conclusions: The Th2 pulmonary pathologies associated with I5/hE2 mice included recruitment of pulmonary effector T cells and increased brochoalveolar Th2 cytokine levels. Conversely, I5/hE2/CD4-/- had only a ~50% reduction in IL-13 levels as compared to I5/hE2 mice, suggesting that a significant portion of IL-13 is non-T cell derived in these mice. I5/hE2/IL-13-/- mice are improved in lung dysfunction and mucus production as compared to I5/hE2 mice. All mice had similar levels of eosinophil degranulation. These results demonstrate a role for non-T cell derived IL-13 that contributes to mucus production and lung dysfunction in a mouse model of chronic severe asthma.
AMPK, a metabolic enzyme, negatively regulate EAE by modulating IL17 response (148.20)
Shridhar, Viji , Giri, Shailendra , Mangalam, Ashutosh K. , Rattan, Ramandeep , Rodriguez, Moses

Mayo Clinic

The Journal of Immunology | January 1, 2023 | Volume: 186 | Issue: 1_Supplement | Pages: 148.20-148.20

10.4049/jimmunol.186.supp.148.20 Get It

Abstract AMPK is an energy sensing metabolic switch in mammalian cells and regulates diverse metabolic pathway in cells. Recently, we observed that AMPK is lost in all immune cells of Experimental autoimmune encephalomyelitis (EAE), widely used animal model for MS. AMPK is lost at protein level in spleen macrophages, total T cells and their subsets (CD4, CD8 and regulatory T cells) isolated from EAE afflicted animals compared to control. To examine the role of AMPK, EAE was induced in Wt (+/+) and AMPKalpha1 null mice (-/-) and found that AMPKalpha1 (-/-) mice exhibited severe EAE disease. AMPKalpha2 is not involved in enhancing the severity of the disease. Moreover, AMPKalpha1 null mice significantly exhibited severe inflammation and demyelination in CNS. Loss of AMPKalpha1 leads to higher production of IL17 cytokine and reduced production of IFNgamma and IL4 under recall response with MOG35-55 as antigen. AMPKalpha1 KO mice exhibited higher number of infiltrated mononuclear cells in CNS and produced higher amount of IL17 significantly compared to Wt mice. Moreover, adoptive transfer of MOG35-55 specific T cells from AMPKalpha1 KO in Wt mice (KO to Wt) induced significantly higher degree of clinical disease compared to adoptive transfer of MOG specific T cells from Wt to Wt mice suggesting loss of AMPK negatively regulate clinical disease of EAE and identify AMPK as a novel therapeutic target for MS.